Next generation weight loss drugs are prohibitively expensive for many in the US who would benefit from taking them—and may remain so, thanks to the phenomenon of patent thickets. Paige Huffman ...

Telehealth companies are aggressively marketing GLP-1s as cosmetic elixirs for anyone who wants to lose a few pounds.

Eli Lilly posts 54% revenue growth with Zepbound, Mounjaro, expanding pipeline, and rising market share. Learn why LLY stock ...

Tan France opens up about 'Queer Eye's final season and his work with Zepbound, focusing on compassion, identity, and clothing without shame.

Several of the environmental advocates and vaccine skeptics who helped propel Kennedy into politics have become impatient with what they view as inadequate action on their priorities.

New GLP-1 weight-loss drugs may preserve muscle, protect skin, and reduce the risk of "Ozempic face." Experts explain what ...

Eli Lilly stock soars on obesity drug success. See here to know why LLY remains a top pick with strong growth prospects and a ...

The demand for weight-loss drugs like Ozempic and Zepbound is higher than ever, so much so that drugmakers Novo Nordisk and Eli Lilly are planning huge expansions in central North Carolina to meet the ...

A massive real-world study comparing tirzepatide and semaglutide reveals both drugs deliver strong, early cardiovascular ...

Eli Lilly has officially entered the elite $1 trillion market-value club, becoming the first pharmaceutical company to reach ...